The Experts below are selected from a list of 16737 Experts worldwide ranked by ideXlab platform
Nicolas Mounier - One of the best experts on this subject based on the ideXlab platform.
-
impact of 18 f fluorodeoxyglucose positron emission tomography response evaluation in patients with high tumor burden follicular Lymphoma treated with immunochemotherapy a prospective study from the groupe d etudes des lymphomes de l adulte and goelams
Journal of Clinical Oncology, 2012Co-Authors: Jehan Dupuis, Nicolas Mounier, Pauline Brice, Herve Tilly, Christelle Tychyjpinel, Andrea Gallamini, Alina Berrioloriedinger, Anne Julian, Pierre Feugier, Pierre SoubeyranAbstract:Purpose [18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with Aggressive Lymphoma, but less is known about the utility of PET in patients with follicular Lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negativ...
-
the germinal center activated b cell subclassification has a prognostic impact for response to salvage therapy in relapsed refractory diffuse large b cell Lymphoma a bio coral study
Journal of Clinical Oncology, 2011Co-Authors: Catherine Thieblemont, Andrew Jack, Josette Briere, Nicolas Mounier, Hansullrich Voelker, Wendy Cuccuini, Edouard Hirchaud, Andreas Rosenwald, Christer Sundstrom, Sergio CogliattiAbstract:Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell Lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial. Patients and Methods Among the 396 patients included on the trial, histologic material was available for a total of 249 patients at diagnosis (n = 189 patients) and/or at relapse (n = 147 patients), which included 87 matched pairs. The patient data were analyzed by immunochemistry for CD10, BCL6, MUM1, FOXP1, and BCL2 expression and by fluorescent in situ hybridization for BCL2, BCL6 and c-MYC breakpoints. The correlation with survival data was performed by using the log-rank test and the Cox model. Results Characteristics of immunophenotype and chromosomal abnormal...
-
the germinal center activated b cell subclassification has a prognostic impact for response to salvage therapy in relapsed refractory diffuse large b cell Lymphoma a bio coral study
Journal of Clinical Oncology, 2011Co-Authors: Catherine Thieblemont, Andrew Jack, Josette Briere, Nicolas Mounier, Hansullrich Voelker, Wendy Cuccuini, Edouard Hirchaud, Andreas Rosenwald, Christer Sundstrom, Sergio CogliattiAbstract:Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell Lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial.
-
chop alone compared with chop plus radiotherapy for localized Aggressive Lymphoma in elderly patients a study by the groupe d etude des lymphomes de l adulte
Journal of Clinical Oncology, 2007Co-Authors: Christophe Bonnet, Catherine Thieblemont, Nicolas Mounier, Gerard Ganem, Christophe Ferme, Bruno Quesnel, Georges Fillet, Thierry Molina, Claude Martin, Christian GisselbrechtAbstract:Purpose Chemoradiotherapy has been considered standard treatment for patients with limited-stage Aggressive Lymphoma on the basis of trials conducted before the introduction of the International Prognostic Index. To evaluate this approach in elderly patients with low-risk localized Lymphoma, we conducted a trial comparing chemoradiotherapy with chemotherapy alone. Patients and Methods Previously untreated patients older than 60 years with localized stage I or II histologically Aggressive Lymphoma and no adverse prognostic factors of the International Prognostic Index were randomly assigned to receive either four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (299 patients) or chemotherapy alone with four cycles of CHOP (277 patients). Results With a median follow-up time of 7 years, event-free and overall survival did not differ between the two treatment groups (P .6 and P .5, respectively). The 5-year estimates of event-free survival were 61% for patients receiving chemotherapy alone and 64% for patients receiving CHOP plus radiotherapy; the 5-year estimates of overall survival were 72% and 68%, respectively. In a multivariate analysis, overall survival was affected by stage II disease (P .001) and male sex (P .03). Conclusion In this large prospective study, CHOP plus radiotherapy did not provide any advantage over CHOP alone for the treatment of low-risk localized Aggressive Lymphoma in elderly patients. J Clin Oncol 25:787-792. © 2007 by American Society of Clinical Oncology
Herve Tilly - One of the best experts on this subject based on the ideXlab platform.
-
RAPID COMMUNICATION LA23 Rearrangements in Non-Hodgkin's Lymphoma: Correlation With Histology, Immunophenotype, Karyotype, and Clinical Outcome in 217 Patients
2013Co-Authors: Christian Bastard, Christophe Fruchart, Clotilde Deweindt, Jeanpierre Kerckaert, Francesco Pezzella, C Duval, M Monconduit, Bernard Lenorm, Annick Rossi, Herve TillyAbstract:We have recently shown that an evolutionary conserved gene LAZ3, encoding a zinc finger protein, is disrupted and overexpressed in some B-cell Lymphomas (mainly with a large cell component) that show chromosomal rearrangements involving 3q27. Because the breakpoints involved in these rearrangements are focused in a narrow major translocation cluster (MTC) on chromosome 3, we used genomic probes from this region to study the molecular rearrangements of LAZ3 in a large series of patients (217) with non-Hodgkin's Lymphoma (NHL). Southern blot analysis showed LAZ3 rearrangement in 43 patients (19.8%). Rearrangement was found in 11 of the 84 patients (13%) with follicular Lymphoma but was most frequent in Aggressive Lymphoma (diffuse mixed, diffuse large cell, and large cell immunoblastic subtypes), in which 31 of the 114 patient
-
impact of 18f fluorodeoxyglucose positron emission tomography response evaluation in patients with high tumor burden follicular Lymphoma treated with immunochemotherapy a prospective study from the groupe d etudes des lymphomes de l adulte and goelams
Journal of Clinical Oncology, 2012Co-Authors: Jeha Dupuis, Herve Tilly, Pauline Ice, Alina Errioloriedinge, Anne Julia, Christelle Tychyjpinel, Nicolas Mounie, Andrea Gallamini, Pierre Feugie, Pierre SoubeyraAbstract:Purpose [18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with Aggressive Lymphoma, but less is known about the utility of PET in patients with follicular Lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negativ...
-
impact of 18 f fluorodeoxyglucose positron emission tomography response evaluation in patients with high tumor burden follicular Lymphoma treated with immunochemotherapy a prospective study from the groupe d etudes des lymphomes de l adulte and goelams
Journal of Clinical Oncology, 2012Co-Authors: Jehan Dupuis, Nicolas Mounier, Pauline Brice, Herve Tilly, Christelle Tychyjpinel, Andrea Gallamini, Alina Berrioloriedinger, Anne Julian, Pierre Feugier, Pierre SoubeyranAbstract:Purpose [18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with Aggressive Lymphoma, but less is known about the utility of PET in patients with follicular Lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negativ...
-
intensive conventional chemotherapy acvbp regimen compared with standard chop for poor prognosis Aggressive non hodgkin Lymphoma
Blood, 2003Co-Authors: Herve Tilly, Eric Lepage, Bertrand Coiffier, Andre Bosly, Georges Fillet, Michel Blanc, Raoul Herbrecht, Michel Attal, Catherine Guettier, Thierry Jo MolinaAbstract:We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in previously untreated patients with poor-risk Aggressive Lymphoma. Patients aged 61 to 69 years who had Aggressive non-Hodgkin Lymphoma with at least one prognostic factor of the age-adjusted international prognostic index (IPI) were included. ACVBP consisted of an induction phase of intensified chemotherapy and central nervous system (CNS) prophylaxis followed by a sequential consolidation phase. Of the 708 patients registered for the study, 635 were eligible. The rate of complete response was 58% in the ACVBP group and 56% in the CHOP group (P =.5). Treatment-related death occurred in 13% of the ACVBP group and 7% of the CHOP group (P =.014). At 5 years, the event-free survival was 39% in the ACVBP group and 29% in the CHOP group (P =.005). The overall survival was significantly longer for patients treated with ACVBP, at 5 years it was 46% compared with 38% for patients treated with CHOP (P =.036). CNS progressions or relapses were more frequent in the CHOP group (P =.004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk Aggressive Lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival. (C) 2003 by The American Society of Hematology.
-
shortened first line high dose chemotherapy for patients with poor prognosis Aggressive Lymphoma
Journal of Clinical Oncology, 2002Co-Authors: Christian Gisselbrecht, Eric Lepage, Thierry Jo Molina, Bertrand Coiffier, Pierre Lederlin, Bruno Quesnel, Georges Fillet, Herve Tilly, Jean Gabarre, Francoise GuilminAbstract:PURPOSE: Randomized trial LNH93-3 was conducted on patients who had poor-prognosis Aggressive Lymphoma and were younger than 60 years with two to three factors of the age-adjusted International Prognostic Index to evaluate the benefit of early high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: Patients were randomized between doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) chemotherapy followed by sequential consolidation and an experimental shortened treatment consisting of three cycles with escalated doses of cyclophosphamide, epirubicin, vindesine, bleomycin, and prednisone and collection of peripheral-blood stem cells. On day 60, HDT was administered with 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, cytarabine, and melphalan followed by ASCT. RESULTS: Eligible patients (n = 370) with Aggressive Lymphoma were analyzed. For ACVBP (181 patients) and HDT (189 patients), respective complete remission rates were 64% and 63%. With a...
Pauline Brice - One of the best experts on this subject based on the ideXlab platform.
-
impact of 18 f fluorodeoxyglucose positron emission tomography response evaluation in patients with high tumor burden follicular Lymphoma treated with immunochemotherapy a prospective study from the groupe d etudes des lymphomes de l adulte and goelams
Journal of Clinical Oncology, 2012Co-Authors: Jehan Dupuis, Nicolas Mounier, Pauline Brice, Herve Tilly, Christelle Tychyjpinel, Andrea Gallamini, Alina Berrioloriedinger, Anne Julian, Pierre Feugier, Pierre SoubeyranAbstract:Purpose [18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with Aggressive Lymphoma, but less is known about the utility of PET in patients with follicular Lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negativ...
-
18f fluoro 2 deoxy d glucose positron emission tomography fdg pet in Aggressive Lymphoma an early prognostic tool for predicting patient outcome
Blood, 2005Co-Authors: Corinne Haioun, Pauline Brice, Emmanuel Itti, A Rahmouni, J D Rain, Karim Belhadj, Philippe Gaulard, Laurent Garderet, E Lepage, F ReyesAbstract:Assessment of early therapeutic response using metabolic imaging is potentially useful to determine prognosis in Aggressive Lymphoma. Between January 2000 and January 2004, 90 patients with newly diagnosed Aggressive Lymphoma (median age 53 years, 94% diffuse large B-cell) were prospectively explored with [ 18 F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) prior to induction chemotherapy, after 2 cycles (“early PET”), and after induction completion. Therapeutic response was evaluated using conventional diagnostic methods at 4 cycles. Induction treatment with an anthracycline-containing regimen was administered to all patients, associated with rituximab in 41%. According to the International Prognostic Index (IPI), 37 patients and 53 patients belonged to the lower- and higher-risk groups, respectively. At midinduction, “early PET” was considered negative in 54 patients and positive in 36. After completion of induction, 83% of PET-negative patients achieved complete remission compared with only 58% of PET-positive patients. Outcome differed significantly between PET-negative and PET-positive groups; the 2-year estimates of event-free survival reached 82% and 43%, respectively ( P P = .006). Predictive value of “early PET” was observed in both the lower-risk and higher-risk groups, indicating prognostic independence from the IPI. Therefore, FDG-PET should be an early guide to first-line strategies in Aggressive Lymphoma. (Blood. 2005;106:1376-1381)
-
acvbp versus chop plus radiotherapy for localized Aggressive Lymphoma
The New England Journal of Medicine, 2005Co-Authors: F Reyes, Eric Lepage, Gerard Ganem, Thierry Jo Molina, Pauline Brice, Bertrand Coiffier, Pierre Morel, Christophe Ferme, Andre Bosly, Pierre LederlinAbstract:Background Chemoradiotherapy is standard treatment for localized Aggressive Lymphoma. To determine the optimal therapy for nonelderly persons with low-risk localized Lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone. Methods Previously untreated patients less than 61 years old with localized stage I or II Aggressive Lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients). Results With a median follow-up of 7.7 years, event-free and overall survival rates were significantly higher in the group given chemotherapy alone than in the group given CHOP plus radiotherapy (P<0.001 and P=0.001, respectively). The five-year...
F Reyes - One of the best experts on this subject based on the ideXlab platform.
-
18f fluoro 2 deoxy d glucose positron emission tomography fdg pet in Aggressive Lymphoma an early prognostic tool for predicting patient outcome
Blood, 2005Co-Authors: Corinne Haiou, Eric Lepage, Emmanuel Itti, A Rahmouni, Philippe Gaulard, Pauline Ice, Jeandidie Rai, Karim Elhadj, Laure Gardere, F ReyesAbstract:Assessment of early therapeutic response using metabolic imaging is potentially useful to determine prognosis in Aggressive Lymphoma. Between January 2000 and January 2004, 90 patients with newly diagnosed Aggressive Lymphoma (median age 53 years, 94% diffuse large B-cell) were prospectively explored with [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) prior to induction chemotherapy, after 2 cycles ("early PET"), and after induction completion. Therapeutic response was evaluated using conventional diagnostic methods at 4 cycles. Induction treatment with an anthracycline-containing regimen was administered to all patients, associated with rituximab in 41%. According to the International Prognostic Index (IPI), 37 patients and 53 patients belonged to the lower- and higher-risk groups, respectively. At midinduction, "early PET" was considered negative in 54 patients and positive in 36. After completion of induction, 83% of PET-negative patients achieved complete remission compared with only 58% of PET-positive patients. Outcome differed significantly between PET-negative and PET-positive groups; the 2-year estimates of event-free survival reached 82% and 43%, respectively (P < .001), and the 2-year estimates of overall survival reached 90% and 61%, respectively (P = .006). Predictive value of "early PET" was observed in both the lower-risk and higher-risk groups, indicating prognostic independence from the IPI. Therefore, FDG-PET should be an early guide to first-line strategies in Aggressive Lymphoma.
-
18f fluoro 2 deoxy d glucose positron emission tomography fdg pet in Aggressive Lymphoma an early prognostic tool for predicting patient outcome
Blood, 2005Co-Authors: Corinne Haioun, Pauline Brice, Emmanuel Itti, A Rahmouni, J D Rain, Karim Belhadj, Philippe Gaulard, Laurent Garderet, E Lepage, F ReyesAbstract:Assessment of early therapeutic response using metabolic imaging is potentially useful to determine prognosis in Aggressive Lymphoma. Between January 2000 and January 2004, 90 patients with newly diagnosed Aggressive Lymphoma (median age 53 years, 94% diffuse large B-cell) were prospectively explored with [ 18 F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) prior to induction chemotherapy, after 2 cycles (“early PET”), and after induction completion. Therapeutic response was evaluated using conventional diagnostic methods at 4 cycles. Induction treatment with an anthracycline-containing regimen was administered to all patients, associated with rituximab in 41%. According to the International Prognostic Index (IPI), 37 patients and 53 patients belonged to the lower- and higher-risk groups, respectively. At midinduction, “early PET” was considered negative in 54 patients and positive in 36. After completion of induction, 83% of PET-negative patients achieved complete remission compared with only 58% of PET-positive patients. Outcome differed significantly between PET-negative and PET-positive groups; the 2-year estimates of event-free survival reached 82% and 43%, respectively ( P P = .006). Predictive value of “early PET” was observed in both the lower-risk and higher-risk groups, indicating prognostic independence from the IPI. Therefore, FDG-PET should be an early guide to first-line strategies in Aggressive Lymphoma. (Blood. 2005;106:1376-1381)
-
acvbp versus chop plus radiotherapy for localized Aggressive Lymphoma
The New England Journal of Medicine, 2005Co-Authors: F Reyes, Eric Lepage, Gerard Ganem, Thierry Jo Molina, Pauline Brice, Bertrand Coiffier, Pierre Morel, Christophe Ferme, Andre Bosly, Pierre LederlinAbstract:Background Chemoradiotherapy is standard treatment for localized Aggressive Lymphoma. To determine the optimal therapy for nonelderly persons with low-risk localized Lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone. Methods Previously untreated patients less than 61 years old with localized stage I or II Aggressive Lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients). Results With a median follow-up of 7.7 years, event-free and overall survival rates were significantly higher in the group given chemotherapy alone than in the group given CHOP plus radiotherapy (P<0.001 and P=0.001, respectively). The five-year...
Catherine Thieblemont - One of the best experts on this subject based on the ideXlab platform.
-
phase ii study of copanlisib a pi3k inhibitor in relapsed or refractory indolent or Aggressive Lymphoma
Annals of Oncology, 2017Co-Authors: Martin Dreyling, Catherine Thieblemont, Franck Morschhauser, Krimo Bouabdallah, Dominique Bron, David Cunningham, Sarit Assouline, Gregor Verhoef, Kim Linton, Umberto VitoloAbstract:Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the a-and delta-isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or Aggressive malignant Lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. Results: Thirty-three patients with indolent Lymphoma and 51 with Aggressive Lymphoma received copanlisib. Follicular Lymphoma (48.5%) and peripheral T-cell Lymphoma (33.3%) were the most common histologic subtypes. Most patients (78.6%) had received prior rituximab and 54.8% were rituximab-refractory. Median duration of treatment was 23 and 8 weeks in the indolent and Aggressive cohorts, respectively (overall range 2-138). Eighty patients were evaluated for efficacy. The objective response rate was 43.7% (14/32) in the indolent cohort and 27.1% (13/48) in the Aggressive cohort; median progression-free survival was 294 days (range 0-874) and 70 days (range 0-897), respectively; median duration of response was 390 days (range 0-825) and 166 days (range 0-786), respectively. Common adverse events included hyperglycemia (57.1%; grade >= 3, 23.8%), hypertension (54.8%; grade >= 3, 40.5%), and diarrhea (40.5%; grade >= 3, 4.8%), all generally manageable. Neutropenia occurred in 28.6% of patients (grade 4, 11.9%). Molecular analyses showed enhanced antitumor activity in tumors with upregulated phosphatidylinositol 3-kinase pathway gene expression. Conclusion: Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and Aggressive malignant Lymphoma. Subtype-specific studies of copanlisib in patients with follicular, peripheral T-cell, and mantle cell Lymphomas are ongoing.
-
the germinal center activated b cell subclassification has a prognostic impact for response to salvage therapy in relapsed refractory diffuse large b cell Lymphoma a bio coral study
Journal of Clinical Oncology, 2011Co-Authors: Catherine Thieblemont, Andrew Jack, Josette Briere, Nicolas Mounier, Hansullrich Voelker, Wendy Cuccuini, Edouard Hirchaud, Andreas Rosenwald, Christer Sundstrom, Sergio CogliattiAbstract:Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell Lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial. Patients and Methods Among the 396 patients included on the trial, histologic material was available for a total of 249 patients at diagnosis (n = 189 patients) and/or at relapse (n = 147 patients), which included 87 matched pairs. The patient data were analyzed by immunochemistry for CD10, BCL6, MUM1, FOXP1, and BCL2 expression and by fluorescent in situ hybridization for BCL2, BCL6 and c-MYC breakpoints. The correlation with survival data was performed by using the log-rank test and the Cox model. Results Characteristics of immunophenotype and chromosomal abnormal...
-
the germinal center activated b cell subclassification has a prognostic impact for response to salvage therapy in relapsed refractory diffuse large b cell Lymphoma a bio coral study
Journal of Clinical Oncology, 2011Co-Authors: Catherine Thieblemont, Andrew Jack, Josette Briere, Nicolas Mounier, Hansullrich Voelker, Wendy Cuccuini, Edouard Hirchaud, Andreas Rosenwald, Christer Sundstrom, Sergio CogliattiAbstract:Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell Lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial.
-
chop alone compared with chop plus radiotherapy for localized Aggressive Lymphoma in elderly patients a study by the groupe d etude des lymphomes de l adulte
Journal of Clinical Oncology, 2007Co-Authors: Christophe Bonnet, Catherine Thieblemont, Nicolas Mounier, Gerard Ganem, Christophe Ferme, Bruno Quesnel, Georges Fillet, Thierry Molina, Claude Martin, Christian GisselbrechtAbstract:Purpose Chemoradiotherapy has been considered standard treatment for patients with limited-stage Aggressive Lymphoma on the basis of trials conducted before the introduction of the International Prognostic Index. To evaluate this approach in elderly patients with low-risk localized Lymphoma, we conducted a trial comparing chemoradiotherapy with chemotherapy alone. Patients and Methods Previously untreated patients older than 60 years with localized stage I or II histologically Aggressive Lymphoma and no adverse prognostic factors of the International Prognostic Index were randomly assigned to receive either four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (299 patients) or chemotherapy alone with four cycles of CHOP (277 patients). Results With a median follow-up time of 7 years, event-free and overall survival did not differ between the two treatment groups (P .6 and P .5, respectively). The 5-year estimates of event-free survival were 61% for patients receiving chemotherapy alone and 64% for patients receiving CHOP plus radiotherapy; the 5-year estimates of overall survival were 72% and 68%, respectively. In a multivariate analysis, overall survival was affected by stage II disease (P .001) and male sex (P .03). Conclusion In this large prospective study, CHOP plus radiotherapy did not provide any advantage over CHOP alone for the treatment of low-risk localized Aggressive Lymphoma in elderly patients. J Clin Oncol 25:787-792. © 2007 by American Society of Clinical Oncology